Prescribing and costs of topical antifungals for onychomycosis by podiatrists in Medicare Part D
SAP Podiatry · 2026-07-25 · 3 · 259
DOI: 10.62486/pod2026259 ↗Abstract
Introduction: Onychomycosis is common in older adults and in diabetes, and podiatrists are frequent first-line providers of nail care, yet little is known about their topical antifungal prescribing in Medicare Part D. Methods: We used the Centers for Medicare and Medicaid Services Part D Prescribers by Provider and Drug public use files for 2014 through 2024, selecting records with podiatry as the prescriber specialty and efinaconazole, tavaborole or ciclopirox as the generic drug. Annual claims, 30-day fills and spending were estimated, log-linear time trends were fitted, and state-level per-beneficiary costs were described for 2024. Results: Annual claims increased from 134,117 to 348,043 and drug costs from 7.7 to 58.1 million USD. Thirty-day fills grew by 9.3% per year (95% CI 7.1-11.5). The share of branded agents rose from 0.1% to 14.3% (
EUVIMED